Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TLPH with free AI briefings, catalyst countdowns, and dilution alerts.

TLPH · TALPHERA, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$14.2M Cash on Hand
12.2mo Cash Runway
Follow TLPH by email Get an email when TLPH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TLPH, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
sufentanil sublingual 30 mcg tablet Moderate-to-severe Acute Pain Phase 3 · NCT02447848 Completed
Zalviso™ Moderate-to-severe Acute Pain Phase 3 · NCT02662764 Completed
Sufentanil Post-Operative Pain Phase 3 · NCT02356588 Completed
Sufentanil NanoTab PCA System/15 mcg Post Operative Pain Phase 3 · NCT01660763 Completed
morphine IV PCA Post-Operative Pain Phase 3 · NCT01539538 Completed
Sufentanil NanoTab Post Operative Pain Phase 2 · NCT00612534 Completed
Sublingual Sufentanil/Triazolam NanoTab™… Sedation Phase 2 · NCT00894699 Completed
Treatment D: Sufentanil NanoTab Oral Pharmacokinetics Phase 1 · NCT01639729 Completed
Treatment D: SSM 30 mcg Healthy Phase 1 · NCT02082236 Completed
Treatment C: Sufentanil NanoTab Buccal Pharmacokinetics Phase 1 · NCT01639729 Completed
Treatment C: SSM 15 mcg Healthy Phase 1 · NCT02082236 Completed
Treatment B: Sufentanil SSM 30 mcg Healthy Phase 1 · NCT02082236 Completed
Treatment B: Sufentanil NanoTab Sublingual Pharmacokinetics Phase 1 · NCT01639729 Completed
Treatment Arm A: Sufenta® Healthy Phase 1 · NCT02082236 Completed
Treatment A: Sufentanil IV Pharmacokinetics Phase 1 · NCT01639729 Completed
40 consecutive doses of SUF NT 15 mcg taken… Plasma Concentrations Phase 1 · NCT01761565 Completed

Also used in these trials (approved or third-party drugs, not TLPH's own candidates): Ketoconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TLPH holds $14.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 12.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 50 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TLPH files for a raise →

👥 Who Owns TLPH

Insiders 19.7% Other 5%+ holders 22.9% Institutions (58 holders) 46.1% Public and other holders 11.3%
HolderTypeShares% of sharesAs of
Rosalind Advisors, Inc. 5%+ holder (13G) 11,877,825 22.86% 2026-09-30
CorMedix Inc.
10% owner
Insider 9,090,909 17.50% 2025-09-07
Orin Hirschman Institution (13G, 5%+) 4,661,502 8.97% 2025-12-31
Nantahala Capital Management, LLC Institution (13G, 5%+) 1,992,519 3.83% 2025-03-31
Vincent J. Angotti
CHIEF EXECUTIVE OFFICER, Director · +959,000 options
Insider 790,767 1.52% 2026-04-02
Raffi Asadorian
Chief Financial Officer · +340,000 options
Insider 85,879 0.17% 2026-04-02
Shakil Aslam
Chief Medical Officer · +285,000 options
Insider 76,542 0.15% 2026-05-20
Badri N Dasu
Chief Engineering Officer · +280,000 options
Insider 71,440 0.14% 2026-04-02
Adrian Adams
Director · +56,300 options
Insider 22,709 0.04% 2026-06-22
Marina Bozilenko
Director · +56,300 options
Insider 14,147 0.03% 2026-06-22
Stephen J Hoffman
Director · +56,300 options
Insider 13,959 0.03% 2026-06-22
Mark A Wan
Director · +56,300 options
Insider 13,959 0.03% 2026-06-22

Share count 51,957,714 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TLPH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TLPH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.